hypertension

Mineralys reports positive data from trial of lorundrostat for hypertension
Mineralys reports positive data from trial of lorundrostat for hypertension
Clinical Trials Arena
Mineralys Therapeutics
clinical trials
hypertension
lorundrostat
Flag link:
Sun Pharma issues recall for more than 34,000 bottles of blood pressure medication
Sun Pharma issues recall for more than 34,000 bottles of blood pressure medication
Endpoints
Sun Pharma
generics
product recalls
Diltiazem
hypertension
Flag link:
IPO Doors Creak Open as Mineralys Seeks $192M
IPO Doors Creak Open as Mineralys Seeks $192M
BioSpace
IPOs
Mineralys Therapeutics
hypertension
MLS-101
Flag link:
Mineralys polishes $100M IPO plans ahead of phase 3 in hypertension
Mineralys polishes $100M IPO plans ahead of phase 3 in hypertension
Fierce Biotech
IPOs
Mineralys
hypertension
Flag link:
Novartis to pay $245 mln to end antitrust cases over Exforge drug generics
Novartis to pay $245 mln to end antitrust cases over Exforge drug generics
Reuters
Novartis
generics
antitrust
legal
Exforge
hypertension
Flag link:
CinCor shares dive after blood pressure drug fails key trial
CinCor shares dive after blood pressure drug fails key trial
BioPharma Dive
CinCor Pharma
clinical trials
hypertension
baxdrostat
Flag link:
Months removed from a $118M Series B, Mineralys pushes ahead with PhII hypertension data
Months removed from a $118M Series B, Mineralys pushes ahead with PhII hypertension data
Endpoints
Mineralys
funding
MLS-101
hypertension
Flag link:
J&J, Idorsia plan filings for aprocitentan data in resistant hypertension
J&J, Idorsia plan filings for aprocitentan data in resistant hypertension
Pharmaphorum
JNJ
Idorsia
aprocitentan
hypertension
resistant hypertension
Flag link:
Orchestra BioMed stays on key in extended study of blood pressure reducing device
Orchestra BioMed stays on key in extended study of blood pressure reducing device
Fierce Biotech
Medtech
devices
Orchestra BioMed
hypertension
TCT
pacemakers
Flag link:
Drugmakers leap back into fading heart drug market
Drugmakers leap back into fading heart drug market
Beckers Hospital Review
Bristol Myers Squibb
Novartis
Merck
Alnylam Pharmaceuticals
Amgen
hypertension
cholesterol
Flag link:
SoniVie receives FDA approval for Pilot study to treat Hypertension with Renal Artery Denervation TIVUS technology
SoniVie receives FDA approval for Pilot study to treat Hypertension with Renal Artery Denervation TIVUS technology
Drugs.com
SoniVie
hypertension
FDA
devices
Medtech
TIVUS
Flag link:
J&J's $230M blood pressure bet hits phase 3 endpoint, but questions linger about blockbuster potential
J&J's $230M blood pressure bet hits phase 3 endpoint, but questions linger about blockbuster potential
Fierce Biotech
JNJ
hypertension
Idorsia
clinical trials
aprocitentan
Flag link:
Pfizer's blood pressure med recall creeps into US as testing flags carcinogen threat
Pfizer's blood pressure med recall creeps into US as testing flags carcinogen threat
Fierce Pharma
Pfizer
hypertension
product recalls
Accupril
Flag link:
Medtronic posts positive 3-year data in renal denervation ahead of key pivotal readout
Medtronic posts positive 3-year data in renal denervation ahead of key pivotal readout
Medtech Dive
devices
Medtech
Medtronic
renal denervation
Symplicity Spyral
hypertension
clinical trials
Flag link:
Pfizer pulls blood pressure medicines in US over cancer-causing impurities
Pfizer pulls blood pressure medicines in US over cancer-causing impurities
Fierce Pharma
Pfizer
hypertension
product recalls
Accuretic
Flag link:
Medtronic misses bid for early FDA OK in renal denervation, stock slides
Medtronic misses bid for early FDA OK in renal denervation, stock slides
Medtech Dive
devices
Medtech
Medtronic
FDA
renal denervation
clinical trials
hypertension
Flag link:
CinCor Raises $143 Million To Fund Innovation in Hypertension Research
CinCor Raises $143 Million To Fund Innovation in Hypertension Research
BioSpace
CinCor Pharma
funding
hypertension
chronic kidney disease
Flag link:
Quiet CinCor Pharma makes some noise with $143M, new trial plans for blood pressure drug
Quiet CinCor Pharma makes some noise with $143M, new trial plans for blood pressure drug
Endpoints
CinCor Pharma
clinical trials
funding
hypertension
CIN-107
Flag link:
Sanofi, eyeing impurity concerns, pulls hypertension meds in Korea and the UK. Could the next big 'sartan' recall be on the horizon?
Sanofi, eyeing impurity concerns, pulls hypertension meds in Korea and the UK. Could the next big 'sartan' recall be on the horizon?
Fierce Pharma
Sanofi
Korea
UK
hypertension
Flag link:
The future of renal denervation
The future of renal denervation
EP Vantage
Medtronic
hypertension
renal denervation
devices
Flag link:

Pages